Literature DB >> 18328072

Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells.

Satoshi Yamagiwa1, Yasunobu Matsuda, Takafumi Ichida, Yutaka Honda, Masaaki Takamura, Satoshi Sugahara, Toru Ishikawa, Shogo Ohkoshi, Yoshinobu Sato, Yutaka Aoyagi.   

Abstract

AIM: Previous studies have revealed that functional impairment of innate immune cells, including natural killer (NK) and natural killer T (NKT) cells, might be associated with the persistence of hepatitis C virus (HCV) infection. However, the involvement of innate immune cells, which predominate in the liver, in therapeutic HCV clearance is still unclear.
METHODS: To clarify the role of intrahepatic innate immune cells in the clinical outcome of patients with chronic hepatitis C (CHC) treated with interferon-alpha plus ribavirin (IFN/RBV), we prospectively investigated the status of NK and NKT cells in paired liver biopsy and peripheral blood (PB) samples obtained from 21 CHC patients before and immediately after IFN/RBV treatment by flow cytometry. Normal liver and PB samples were obtained from 10 healthy donors for living donor liver transplantation.
RESULTS: Before treatment, intrahepatic NK and NKT cells constituted a significantly lower proportion in CHC patients than in healthy individuals (P < 0.05). After IFN/RBV treatment, the proportions and absolute numbers of CD3(-)CD161(+) NK and CD3(+)CD56(+) NKT cells in the liver, but not in PB, were significantly increased in sustained responders (SR) as compared with poor responders (P < 0.05). The proportion of CD3(+)CD161(+) NKT cells was also increased in the liver of SR after the treatment. Moreover, there was a striking increase of activated CD152(+) cells among CD3(+)CD56(+) NKT cells in the liver of SR (P = 0.041).
CONCLUSION: These findings demonstrate that sustained response to IFN/RBV treatment for patients with CHC is closely associated with increased dynamism of NK and NKT cells in the liver.

Entities:  

Year:  2008        PMID: 18328072     DOI: 10.1111/j.1872-034X.2008.00317.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  20 in total

1.  Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.

Authors:  Sung-Jae Park; Young S Hahn
Journal:  Rev Infect       Date:  2010-07-01

2.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 3.  Targeting the diverse immunological functions expressed by hepatic NKT cells.

Authors:  Caroline C Duwaerts; Stephen H Gregory
Journal:  Expert Opin Ther Targets       Date:  2011-05-13       Impact factor: 6.902

Review 4.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

5.  Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines.

Authors:  Damien Sène; Franck Levasseur; Michal Abel; Marion Lambert; Xavier Camous; Céline Hernandez; Véronique Pène; Arielle R Rosenberg; Evelyne Jouvin-Marche; Patrice N Marche; Patrice Cacoub; Sophie Caillat-Zucman
Journal:  PLoS Pathog       Date:  2010-11-11       Impact factor: 6.823

6.  Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.

Authors:  J R Vidal-Castiñeira; A López-Vázquez; R Díaz-Peña; R Alonso-Arias; J Martínez-Borra; R Pérez; J Fernández-Suárez; S Melón; J Prieto; L Rodrigo; C López-Larrea
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

7.  Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.

Authors:  Sahar Essa; Raja'a Al-Attiyah; Iqbal Siddique; Widad Al-Nakib
Journal:  Med Princ Pract       Date:  2020-09-23       Impact factor: 1.927

Review 8.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

Review 9.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

10.  Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.

Authors:  Masahiro Ohira; Kohei Ishiyama; Yuka Tanaka; Marlen Doskali; Yuka Igarashi; Hirotaka Tashiro; Nobuhiko Hiraga; Michio Imamura; Naoya Sakamoto; Toshimasa Asahara; Kazuaki Chayama; Hideki Ohdan
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.